0001437749-22-020338.txt : 20220812
0001437749-22-020338.hdr.sgml : 20220812
20220812160219
ACCESSION NUMBER: 0001437749-22-020338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220810
FILED AS OF DATE: 20220812
DATE AS OF CHANGE: 20220812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGGINS JOHN L
CENTRAL INDEX KEY: 0001208906
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 221159904
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-08-10
0000842023
BIO-TECHNE Corp
TECH
0001208906
HIGGINS JOHN L
11085 NORTH TORREY PINES ROAD
SUITE 300
LA JOLLA
CA
92037
1
Common Stock
2022-08-10
4
M
0
3400
66.90
A
8006
D
Common Stock
2022-08-10
4
S
0
900
373.9918
D
7106
D
Common Stock
2022-08-10
4
S
0
100
374.8950
D
7006
D
Common Stock
2022-08-10
4
S
0
992
380.153
D
6014
D
Common Stock
2022-08-11
4
S
0
504
385.4694
D
5510
D
Common Stock
2022-08-11
4
S
0
8
380.71
D
5502
D
Stock Option (right to buy)
66.90
2022-08-10
4
M
0
3400
0
D
2012-10-25
2022-10-24
Common Stock
3400
0
D
Stock Option (right to buy)
87.3900
2013-10-31
2023-10-30
Common Stock
4000
4000
D
Stock Option (right to buy)
91.7800
2014-10-30
2024-10-30
Common Stock
4000
4000
D
Stock Option (right to buy)
87.3400
2016-10-29
2025-10-28
Common Stock
4260
4260
D
Stock Option (right to buy)
101.1900
2017-10-26
2026-10-26
Common Stock
3985
3985
D
Stock Option (right to buy)
125.0500
2018-10-25
2027-10-27
Common Stock
3125
3125
D
Stock Option (right to buy)
179.8400
2019-10-24
2028-10-25
Common Stock
1898
1898
D
Stock Option (right to buy)
201.6400
2020-10-24
2029-10-24
Common Stock
2011
2011
D
Stock Option (right to buy)
255.6900
2021-10-28
2030-10-29
Common Stock
1507
1507
D
Stock Option (right to buy)
515.2400
2031-10-28
Common Stock
633
633
D
The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 373.8600 to 374.3300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 374.8950 to 374.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 380.0000 to 380.4400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 385.2900 to 385.8900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Brenda S. Furlow, Attorney-in-Fact
2022-08-12